文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨肉瘤的发病机制与治疗研究进展。

Research progress in the mechanism and treatment of osteosarcoma.

机构信息

Department of Joint and Sports Medicine, The Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, China.

Department of Pathology, The Second People's Hospital Of Jining, Jining, Shandong 272049, China.

出版信息

Chin Med J (Engl). 2023 Oct 20;136(20):2412-2420. doi: 10.1097/CM9.0000000000002800. Epub 2023 Aug 31.


DOI:10.1097/CM9.0000000000002800
PMID:37649421
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10586865/
Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor that more commonly occurs in children and adolescents. The most commonly used treatment for OS is surgery combined with chemotherapy, but the treatment outcomes are typically unsatisfactory. High rates of metastasis and post-treatment recurrence rates are major challenges in the treatment of OS. This underlines the need for studying the in-depth characterization of the pathogenetic mechanisms of OS and development of more effective therapeutic modalities. Previous studies have demonstrated the important role of the bone microenvironment and the regulation of signaling pathways in the occurrence and development of OS. In this review, we discussed the available evidence pertaining to the mechanisms of OS development and identified therapeutic targets for OS. We also summarized the available treatment modalities for OS and identified future priorities for therapeutics research.

摘要

骨肉瘤(OS)是最常见的原发性恶性骨肿瘤,更常见于儿童和青少年。OS 的最常用治疗方法是手术联合化疗,但治疗效果通常不理想。高转移率和治疗后复发率是 OS 治疗的主要挑战。这凸显了深入研究 OS 发病机制和开发更有效的治疗方法的必要性。先前的研究表明,骨微环境的重要作用和信号通路的调节在 OS 的发生和发展中起重要作用。在这篇综述中,我们讨论了 OS 发展机制的现有证据,并确定了 OS 的治疗靶点。我们还总结了 OS 的现有治疗方法,并确定了未来治疗研究的重点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/75afa9bd2bfb/cm9-136-2412-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/b129aba7be16/cm9-136-2412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/108dc12493e5/cm9-136-2412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/6e67967470d8/cm9-136-2412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/6f5774b70fce/cm9-136-2412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/0ea67dc5b824/cm9-136-2412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/75afa9bd2bfb/cm9-136-2412-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/b129aba7be16/cm9-136-2412-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/108dc12493e5/cm9-136-2412-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/6e67967470d8/cm9-136-2412-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/6f5774b70fce/cm9-136-2412-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/0ea67dc5b824/cm9-136-2412-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9fc/10586865/75afa9bd2bfb/cm9-136-2412-g006.jpg

相似文献

[1]
Research progress in the mechanism and treatment of osteosarcoma.

Chin Med J (Engl). 2023-10-20

[2]
MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.

Mol Carcinog. 2017-6

[3]
Innovative approaches for treatment of osteosarcoma.

Exp Biol Med (Maywood). 2022-2

[4]
Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma.

Curr Med Chem. 2022

[5]
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.

Int J Mol Sci. 2016-4-6

[6]
Autophagy and its role in osteosarcoma.

Cancer Med. 2023-3

[7]
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?

Int J Mol Sci. 2019-7-31

[8]
Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.

Int Immunopharmacol. 2023-8

[9]
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.

Front Immunol. 2022

[10]
Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.

Sci Rep. 2018-3-8

引用本文的文献

[1]
KIAA1429 Silencing ameliorates osteosarcoma progression through promoting ferroptosis via Nrf2/NQO1 axis.

Inflamm Res. 2025-8-22

[2]
DTX1 Modulates Microglial M1 Polarization and Exacerbates Neuroinflammation in Traumatic Brain Injury Model Rats through NF-κB/IRF5.

Mol Neurobiol. 2025-7-15

[3]
Glutathione peroxidase 7 knockdown inhibits growth, invasion, and migration while enhancing oxidative stress and ferroptosis in osteosarcoma cells.

J Bone Oncol. 2025-5-31

[4]
Coumarin derivatives as anticancer agents targeting PI3K-AKT-mTOR pathway: a comprehensive literature review.

Med Oncol. 2025-6-30

[5]
IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma.

Discov Oncol. 2025-5-26

[6]
Unveiling the effects of GSK126 on osteosarcoma cells implications for apoptosis, autophagy, and cellular migration.

Discov Oncol. 2025-2-27

[7]
Daidzin improves the cisplatin chemosensitivity for osteosarcoma via binding to β-catenin protein and suppressing the wnt pathway.

Sci Rep. 2025-2-14

[8]
Gelatin-based biomaterials as a delivery strategy for osteosarcoma treatment.

Front Pharmacol. 2025-1-28

[9]
The role of disulfidptosis-associated LncRNA-LINC01137 in Osteosarcoma Biology and its regulatory effects on macrophage polarization.

Funct Integr Genomics. 2024-11-22

[10]
YB1 and its role in osteosarcoma: a review.

Front Oncol. 2024-10-21

本文引用的文献

[1]
Autophagy and its role in osteosarcoma.

Cancer Med. 2023-3

[2]
Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.

Front Immunol. 2022

[3]
Role of extracellular vesicles in osteosarcoma.

Int J Med Sci. 2022

[4]
METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma.

EBioMedicine. 2022-8

[5]
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.

Cancer Lett. 2022-6-28

[6]
Research Progress of Exosome-Loaded miRNA in Osteosarcoma.

Cancer Control. 2022

[7]
A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.

Lab Invest. 2022-4

[8]
T cell exhaustion drives osteosarcoma pathogenesis.

Ann Transl Med. 2021-9

[9]
Exosomal transfer of miR-769-5p promotes osteosarcoma proliferation and metastasis by targeting DUSP16.

Cancer Cell Int. 2021-10-18

[10]
Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma.

Mol Ther Oncolytics. 2021-8-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索